AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

EP: 4.Current Treatment Landscape for AL Amyloidosis

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

Now Viewing

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Current advancements in amyloidosis treatment involve critical phase 3 trials evaluating birtamimab and standard care for stage 4 cardiac amyloidosis. These trials are pivotal for potential drug licensing and moving the field forward. The ongoing AFFIRM-AL trial, specifically for patients with Mayo stage IV disease, aims to assess the impact of antifibril antibodies alongside standard care therapies like cyclophosphamide-bortezomib-dexamethasone (CyBorD) and a CD38 antibody. The panelists are eagerly anticipating trial results, hoping for improved hematologic and organ responses simultaneously, which would address the current lag in organ response. Recognizing the importance of these trials, clinicians’ focus on untreated patients reflects lessons learned from earlier studies, emphasizing statistical relevance and higher potential benefits. The experts emphasize accessing these trials at specialized centers for collecting crucial data and understanding potential benefits for patients.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.